Antibiofilm Strategies: Current and Future Applications to Prevent, Control and Eradicate Biofilms
இந்த மின்புத்தகத்தைப் பற்றி
Antibiofilm strategies, such as chemical and enzymatic treatments, surface modification and coatings, quorum sensing inhibition and dispersal induction, phage therapy, cold plasma treatment, hyperbaric oxygen treatment, and metal-based nanomedicine are covered, among many others.
This book contributes to the UN’s Sustainable Development Goal 3: Good Health and Well-Being and is a valuable resource for healthcare professionals, microbiologists, academics and for educators to inform curricula of universities and colleges.
ஆசிரியர் குறிப்பு
Dr Katharina Richter is an enthusiastic biomedical scientist, dedicated to improve therapies against antibiotic-resistant bacteria and biofilms. She has global work and research stints in Germany, Switzerland, Denmark, Belgium, The Netherlands, New Zealand and Australia. A trained pharmacist she completed her PhD in medicine & applied microbiology in 2017 and started her own research group in 2019 at the University of Adelaide, Australia. Her group has two priorities: i) developing new treatments against biofilm infections and bringing them from bench to bedside, and ii) improving health literacy of the society by effective science communication through public speaking, science outreach activities and STEM workshops at schools.
Katharina collaborates with scientists, clinicians and industry partners to ensure a real life impact of her work.
Dr Kasper Kragh obtained his Ph.D. in Health and Medical Sciences from the University of Copenhagen, Denmark. He has worked for over ten years at the Costerton Biofilm Center with a wide range of aspects concerning bacterial biofilm. During his scientific career, Kasper has focused his attention on the use of microscopy in biofilm research and how the phenotype of non-attached biofilm aggregates is involved and influences both pathogenesis and in vitro systems. The study of the mechanisms behind the chronic infectious state of biofilms, in in vivo-like in vitro models and direct infections, has been a red thread throughout his career.
